Lenvatinib is an oral medication used to treat liver cancer (hepatocellular carcinoma). It works by blocking certain proteins that help cancer cells grow and spread. This medication is used when other treatments, like TACE (Trans-Arterial Chemoembolization), haven’t been completely successful. It can help control tumor growth in patients who are waiting for a liver transplant.

TACE (Trans-Arterial Chemoembolization) is a medical procedure where doctors inject chemotherapy medication directly into the blood vessels that feed the liver tumor, followed by materials that block these blood vessels. This treatment aims to shrink the tumor by cutting off its blood supply while delivering chemotherapy directly to the cancer cells.

Hepatocellular Carcinoma (HCC) – A primary liver cancer that begins in the main type of liver cells (hepatocytes). The disease typically develops in people with chronic liver diseases, such as cirrhosis. HCC usually starts as several small cancer nodules throughout the liver, rather than a single large tumor. As the disease progresses, these nodules can grow larger and spread to other parts of the liver. The condition affects liver function and can cause the organ to work less efficiently over time. Non-resectable HCC refers to tumors that cannot be completely removed through surgery due to their size, location, or number.